Home » Newsletters » BioWorld Science

BioWorld Science

May 21, 2012

View Archived Issues

Data reported on effects of HSC gene therapy for metachromatic leukodystrophy

Sonic hedgehog pathway inhibitors disclosed by U.S. researchers

Teva Pharmaceutical Industries patents novel compounds for MS

Novel histone deacetylase inhibitors prepared by Georgia Tech Research Corp.

Promising results reported for first patients in phase I trial of VRX-007

In vivo studies show new therapeutic potential for CDDO-Me

Daclatasvir shows promise in difficult-to-treat populations

Alisporivir results in hepatitis C virus genotypes 1, 2 and 3 reported

Novel protease inhibitors for HIV patented

Monash University presents new antimicrobial peptides

Merz Pharma designs novel cognition-enhancing drugs

Novel AMPK activators designed by Roche

Anti-marinobufagenin antibody studied in salt-sensitive hypertension

Taisho updates pipeline progress for fiscal 2011

Shionogi reviews pipeline progress of fourth quarter of fiscal 2011

Janssen gains Japanese approval for anti-HIV agent

Agilent set to acquire leading cancer diagnostic company

ArQule and Daiichi Sankyo complete patient recruitment in phase III tivantinib study

Ocera obtains CE Mark for Zysa

Half of target patient population recruited in phase III tasquinimod study

ASLAN obtains global rights to Almirall's DHOdehase inhibitor

Pharmaxis submits NDA for Bronchitol

Helix BioPharma receives clearance for European phase III study in low-grade cervical lesions

MRC Technology and Queen Mary University of London enter multiple GPCR collaborations

Popular Stories

NIH changes set industry up for workforce, ideas drought
BioWorld
On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...
Today's news in brief
BioWorld
BioWorld briefs for March 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for March 12, 2025
At CROI, HIV cure trials raise hopes for broader applicability
BioWorld
At the 2025 meeting of the Conference on Retroviruses and Opportunistic Infections (CROI) it was the best of times, it was the worst of times. On the first full...
Hummingbird migrates ADCs, tech to newco Callio’s $187M debut
BioWorld
Antibody-drug conjugate (ADC)-focused Callio Therapeutics debuted on March 3 with the closing of a $187 million series A financing round based on cancer drug...